In a nutshell This trial is aiming to examine the effectiveness of an experimental drug, AMXI-5001, in patients with advanced breast cancer. The main outcomes that are to be measured in this trial are side effects and the response to treatment. This trial is going to be carried out in California, Tennessee, and Florida, the United States. The...
Read MoreCurrent disease status-Recurrent cancer-Metastatic recurrence Posts on Medivizor
Does olaparib increase survival in patients with metastatic castration-resistant prostate cancer?
In a nutshell This study assessed whether olaparib (Lynparza) affected progression-free survival (PFS; survival without cancer worsening) in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain genetic mutations (abnormalities). The study found that olaparib improved PFS in these patients. Some...
Read MoreWhat are the outcomes of sipuleucel-T treatment for patients with metastatic castration-resistant prostate cancer?
In a nutshell This study evaluated the safety and effectiveness of sipuleucel-T (Provenge) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The authors found that the average survival after sipuleucel-T treatment was 30.7 months and that 13.7% of patients experienced side effects. Some background...
Read MoreSearching for patients with advanced prostate cancer to test a new drug combination
In a nutshell This phase 3 trial will evaluate the safety and effectiveness of olaparib (Lynparza) and abiraterone (Zytiga) combination in prostate cancer. The main outcome will be the rate of survival without cancer growing or spreading. The details Prostate cancer (PC) is cancer that originates in the prostate gland. When cancer progresses to a...
Read MoreSearching for patients with castration resistant metastatic prostate cancer to test cabazitaxel and abiraterone
In a nutshell This trial is examining the safety and effectiveness of cabazitaxel (Jevtana) with abiraterone acetate (Zytiga) compared to abiraterone acetate alone for metastatic (cancer that has spread) castration-resistant prostate cancer (cancer that is no longer responding to hormone therapy). The main outcome measured will be the...
Read MoreDoes a medication used to treat diabetes have anti-cancer potential?
In a nutshell This study looked at the anticancer effect of metformin (Glucophage), a drug commonly used to treat type 2 diabetes. The authors concluded that metformin in combination with current cancer therapies such as chemotherapy improved progression free survival in patients with advanced non-small-cell lung cancer. Some background Patients with...
Read MoreCabazitaxel versus docetaxel in men with advanced, hormone-resistant prostate cancer
In a nutshell The authors aimed to determine whether cabazitaxel (Jevtana) was superior to docetaxel (Taxotere) in improving overall survival in patients with advanced, hormone-resistant prostate cancer who had not received previous treatment with chemotherapy. The authors concluded that cabazitaxel was not superior...
Read MoreLooking for men with castration-resistant prostate cancer to test ipatasertib plus abiraterone/prednisone
In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...
Read MoreAn analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer
In a nutshell This study aimed to determine which patients benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination. Some background A main treatment option for prostate cancer is androgen deprivation...
Read MoreSearching for patients with HER2 positive metastatic breast cancer to test palbociclib in combination with standard therapy.
In a nutshell This phase 3 trial aims to evaluate the effectiveness of palbociclib (Ibrance) in combination with standard treatments for HER2 positive breast cancer. The main outcome to be investigated is progression free survival. This trial is taking place in Alabama, Illinois, Iowa, Nebraska and Oklahoma in the United States. The details...
Read MoreLooking for participants with advanced melanoma to test the effectiveness of a combined immunotherapy
In a nutshell This phase 2 trial aims to test the effectiveness of the combined treatment of three different immunotherapies. The main outcomes of this trial will be the tumor response to the treatment and the overall survival. The details Immunotherapies stimulate the immune system to attack and kill cancer cells the way it would a virus or...
Read MoreThe use of biomarkers in advanced prostate cancer with bone tumors
In a nutshell The aim of this study was to determine the effect of biomarkers to tailor therapy in advanced prostate cancer in patients receiving abiraterone (Zytiga) treatment. The authors concluded that alkaline phosphatase (ALP- protein elevated in the blood), lactate dehydrogenase (LDH – protein involved in tumor growth) and prostate...
Read More